Maternal Opioid Treatment: Human Experimental Research – Data Yield Appropriate Decisions

Maternal Opioid Treatment: Human Experimental Research – Data Yield Appropriate Decisions

Publication date: Aug 08, 2019

This study will compare medically-supervised withdrawal (MSW, ‘detoxification’) to opioid agonist treatment (OAT, ‘maintenance’) with buprenorphine for pregnant women with opioid use disorder in terms of maternal, fetal, and neonatal outcomes. Outcomes will be assessed during pregnancy, at birth and for 12 months postpartum. This study has the potential to impact health service policy and practices in terms of the treatment options of pregnant women with opioid use disorder.

Concepts Keywords
Agonist Opioids
Buprenorphine RTT
Detoxification Women’s health
Fetal Midwifery
Fetus Drug rehabilitation
Neonatal Morphinans
Opioid Buprenorphine
Postpartum Opioid agonist treatment
Pregnancy Postpartum period
Vermont Pregnancy
Childbirth

Semantics

Type Source Name
gene UNIPROT OAT
drug DRUGBANK Buprenorphine
gene UNIPROT IMPACT
disease MESH fetus
gene UNIPROT NR4A2
gene UNIPROT ALG3
disease MESH Syndrome
disease DOID Syndrome

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *